Given the strong results, Cellceutix is continuing to treat animals with Kevetrin™ for a second cycle to further evaluate efficacy. Additional cycles of administration could also establish that Kevetrin does not induce resistance to the cancer cells.
“Kevetrin™ simply continues to impress,” stated Dr. Krishna Menon, CSO of Cellceutix. “In reality, the nearly 100% tumor growth delay was underestimated as the tumors in one of the Kevetrin treated mice never reached 500mm(3). Therefore, it had to be omitted from that set of data; otherwise the figure would have been even higher. Preliminary data from the second cycle of dosing, initiated when tumors had reached 2200mm(3), is again showing reduction of tumor growth, reinforcing the idea of no resistance towards Kevetrin™ developing and the sheer potency of our compound. In all my years as a researcher, I have never seen anything like Kevetrin™.”
“We look forward to providing our investors with a multitude of data and updates in the upcoming weeks,” commented Cellceutix CEO Leo Ehrlich. “We are eagerly awaiting the conclusion of the pancreatic research. Additionally, we are reaching the final stages of the procedural process with one of the United States’ most prominent cancer centers regarding the Phase I clinical trial which we will be able to disclose shortly. The culmination of this process is the filing of the Investigational New Drug Application (IND) with the US FDA.”
About Cellceutix
Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.
Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of this website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The following news is published as information only for our readers. otcshowcase.com is a third party publisher of news and research .Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising.
Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/?page_id=190.
Cellceutix Corp. (CTIX) Stock Quote and News:
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the 
0 comments
Add your comment
Commenting is allowed only for registered users.